Long-term debt 6,202 6,675
Other long-term liabilities 5,248 4,395
Stockholders' equity 473,700 479,648
Total liabilities & equity $565,532 $572,735
THIRD QUARTER FYE08
CONSOLIDATED STATEMENTS OF INCOME ADJUSTED FOR CERTAIN
ITEMS
12/29/07
Restructuring
12/29/07 As Costs 12/29/07 As
Reported (3) Adjusted (4)
NET REVENUES $134,587 $0 $134,587
Gross profit 66,558 0 66,558
R&D 5,529 0 5,529
S,G&A 41,432 1,225 40,207
Operating expenses 46,961 1,225 45,736
Operating income 19,597 (1,225) 20,822
Interest income, net 1,070 0 1,070
Other income/(expense), net 225 0 225
Income before taxes 20,892 (1,225) 22,117
Tax expense 6,538 (386) 6,924
NET INCOME $14,354 ($839) $15,193
Net income per common share
assuming dilution $0.54 ($0.03) $0.57
Weighted average number of shares
Basic 25,500 25,500 25,500
Diluted 26,437 26,437 26,437
Profit Margins:
Gross profit
'/>"/>
| SOURCE Haemonetics Corporation Copyright©2008 PR Newswire. All rights reserved |